Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C.

Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.

2.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

3.

A two-drug regimen for antiretroviral therapy.

Kroidl A, Eberle J.

Lancet. 2019 Jan 12;393(10167):106-108. doi: 10.1016/S0140-6736(18)32783-1. Epub 2018 Nov 9. No abstract available.

PMID:
30420122
4.

Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B.

Atanga PN, Ndetan HT, Fon PN, Meriki HD, Muffih TP, Achidi EA, Hoelscher M, Kroidl A.

BMC Pregnancy Childbirth. 2018 Oct 25;18(1):418. doi: 10.1186/s12884-018-2058-9.

5.

Accuracy and Operational Characteristics of Xpert Human Immunodeficiency Virus Point-of-Care Testing at Birth and Until Week 6 in Human Immunodeficiency Virus-exposed Neonates in Tanzania.

Sabi I, Mahiga H, Mgaya J, Geisenberger O, Kastner S, Olomi W, Saathoff E, Njovu L, Lueer C, France J, Maboko L, Ntinginya NE, Hoelscher M, Kroidl A.

Clin Infect Dis. 2019 Feb 1;68(4):615-622. doi: 10.1093/cid/ciy538.

6.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

7.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.

Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C.

J Virol. 2017 Aug 24;91(18). pii: e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15.

8.
9.

Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.

Kroidl A, Ello F, Mgaya J, Lennemann T, Moh R, Maganga L, Eholie S, Pruvost A, Saathoff E, Girard PM, Zuhse R, von Massow F, Anglaret X, Hoelscher M, Danel C; FATI-1 study team.

AIDS. 2017 Feb 20;31(4):501-509. doi: 10.1097/QAD.0000000000001362.

10.

Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV-positive women initiating 'Option B+' in the South West Region.

Atanga PN, Ndetan HT, Achidi EA, Meriki HD, Hoelscher M, Kroidl A.

Trop Med Int Health. 2017 Feb;22(2):161-170. doi: 10.1111/tmi.12816. Epub 2016 Dec 18.

11.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

12.

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.

Kroidl I, Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, Kalomo M, Minja LT, Kowuor D, Saathoff E, Kroidl A, Heinrich N, Maboko L, Bates M, O'Grady J, Zumla A, Hoelscher M, Rachow A.

Eur Respir J. 2015 Sep;46(3):761-70. doi: 10.1183/09031936.00003315. Epub 2015 Jun 25.

13.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

14.

Evaluation of health research capacity strengthening trainings on individual level: validation of a questionnaire.

Huber J, Bauer D, Hoelscher M, Kapungu J, Kroidl A, Lennemann T, Maganga L, Opitz O, Salehe O, Sigauke A, Fischer MR, Kiessling C.

J Eval Clin Pract. 2014 Aug;20(4):390-5. doi: 10.1111/jep.12143. Epub 2014 May 15.

PMID:
24828323
15.

Evidence for significant influence of host immunity on changes in differential blood count during malaria.

Berens-Riha N, Kroidl I, Schunk M, Alberer M, Beissner M, Pritsch M, Kroidl A, Fröschl G, Hanus I, Bretzel G, von Sonnenburg F, Nothdurft HD, Löscher T, Herbinger KH.

Malar J. 2014 Apr 23;13:155. doi: 10.1186/1475-2875-13-155.

16.

Non-healing old world cutaneous leishmaniasis caused by L. infantum in a patient from Spain.

Kroidl A, Kroidl I, Bretzel G, Löscher T.

BMC Infect Dis. 2014 Apr 16;14:206. doi: 10.1186/1471-2334-14-206.

17.

Low specificity of determine HIV1/2 RDT using whole blood in south west Tanzania.

Kroidl I, Clowes P, Mwalongo W, Maganga L, Maboko L, Kroidl AL, Geldmacher C, Machibya H, Hoelscher M, Saathoff E.

PLoS One. 2012;7(6):e39529. doi: 10.1371/journal.pone.0039529. Epub 2012 Jun 29.

18.

Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study.

Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, Kowour D, Rojas-Ponce G, Kroidl A, Maboko L, Heinrich N, Reither K, Hoelscher M.

Clin Infect Dis. 2012 May;54(10):1388-96. doi: 10.1093/cid/cis190. Epub 2012 Apr 3.

PMID:
22474220
19.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML.

J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299.

20.

Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child.

Kroidl A, Huck K, Weinspach S, Gudowius S, Mackenzie CR, Oette M, Häussinger D, Niehues T.

Scand J Infect Dis. 2006;38(8):716-8.

PMID:
16857624
21.

Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.

Feldt T, Oette M, Kroidl A, Goebels K, Fritzen R, Kambergs J, Kappert G, Vogt C, Wettstein M, Häussinger D.

Infection. 2006 Apr;34(2):55-61.

PMID:
16703293
22.

Predictors of short-term success of antiretroviral therapy in HIV infection.

Oette M, Kroidl A, Göbels K, Stabbert A, Menge M, Sagir A, Kuschak D, O'hanley T, Bode JG, Häussinger D.

J Antimicrob Chemother. 2006 Jul;58(1):147-53. Epub 2006 May 10.

PMID:
16687458
23.

Prevalence of oral lesions and periodontal diseases in HIV-infected patients on antiretroviral therapy.

Kroidl A, Schaeben A, Oette M, Wettstein M, Herfordt A, Häussinger D.

Eur J Med Res. 2005 Oct 18;10(10):448-53.

PMID:
16287607
24.

Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.

Oette M, Kurowski M, Feldt T, Kroidl A, Sagir A, Vogt C, Wettstein M, Häussinger D.

J Antimicrob Chemother. 2005 Aug;56(2):416-9. Epub 2005 Jun 27.

PMID:
15983027
25.

Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.

Feldt T, Oette M, Kroidl A, Göbels K, Leidel R, Sagir A, Kuschak D, Häussinger D.

Eur J Med Res. 2005 Jan 28;10(1):7-10.

PMID:
15737947
26.

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases.

Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, Kroidl A, Bogner JR, Spengler U, Rockstroh JK.

J Viral Hepat. 2005 Mar;12(2):207-11.

PMID:
15720537
27.
28.

[SARS--the facts. Transmission, diagnosis and managing suspected cases].

Feldt T, Oette M, Kroidl A, Göbels K, Richter J, Häussinger D.

MMW Fortschr Med. 2003 May 8;145(19):36-40. German.

PMID:
12813976
29.

Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients.

Oette M, Juretzko P, Kroidl A, Sagir A, Wettstein M, Siegrist J, Häussinger D.

AIDS Patient Care STDS. 2002 Sep;16(9):413-7.

PMID:
12396693
30.

[Current trends and research emphasis. Epidemiology, resistance testing, vaccination strategies].

Oette M, Kroidl A, Göbels K, Heintges T, Wettstein M, Häussinger D, Hamouda O, Kaiser R, Beerenwinkel N.

MMW Fortschr Med. 2002 Apr 9;144 Suppl 1:73-6. German. No abstract available.

PMID:
12043081
31.

Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis.

Daniel PT, Kroidl A, Cayeux S, Scholz C, Sturm I, Blankenstein T, Pezzutto A, Dörken B.

Adv Exp Med Biol. 1998;451:265-76. No abstract available.

PMID:
10026884
32.

Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.

Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, Pezzutto A.

Blood. 1998 Dec 15;92(12):4750-7.

PMID:
9845541
33.

Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.

Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B.

J Immunol. 1997 Oct 15;159(8):3808-15.

PMID:
9378968

Supplemental Content

Loading ...
Support Center